INVESTOR RELATIONS

This page is published for information only. It is not an invitation to invest, an offer, or a prospectus, and no securities are being offered through this website.

THE COMPANY

RLES AI® is developed and published by MCD Technology Investments Inc. The clinical rule set, the software and the RLES AI trademark are owned by the company; no third party holds rights over them. The company is privately held.

WHAT WE BUILD

A clinical decision support platform for refractive laser eye surgery and cataract/RLE planning. The product is used by surgeons, not patients: it does not diagnose, it does not set indications, and the final clinical decision rests with the treating surgeon in every case. What makes it hard to copy is not the model but the rule set that constrains it — thresholds distilled from a large real-world surgical series, each carrying its own source label, alongside device nomograms taken verbatim from manufacturers' published tables.

WHERE WE STAND

• Fifteen clinical modules are complete and in clinical pilot with registered surgeons; the live surgeon count is published on the home page
• Full platform launch is targeted for November 2026 in Türkiye and the European Union; United States availability depends on the regulatory route described below
• The platform serves in sixteen languages

GOVERNANCE AND INDEPENDENCE

Clinical rules are developed with practising ophthalmic surgeons who serve on the Medical Advisory Board. No member of that board has any financial interest, monetary or in kind, in the clinical analysis and validation work carried out on this platform. Website content is medically reviewed by named ophthalmologists under a published Editorial Policy. In data protection terms the treating physician is the controller and the company processes on the physician's behalf and instruction.

REGULATORY POSITION

INVESTOR INFORMATION MEMORANDUM

A confidential information memorandum is available to qualified parties on request. It covers the problem and the product, the origin of the clinical rule set, the market, the business model, the regulatory position in detail and the principal risks. It deliberately contains no financial projections, valuation or round terms; those are shared after a mutual non-disclosure agreement, together with a product demonstration on a real case.

To request it, use the information request form on the home page and state that you are writing about investor relations. A real person answers.

PRESS AND MEDIA

Press releases and media enquiries are handled on the Press & Media page.

IMPORTANT NOTICE

Nothing on this page constitutes an offer to sell or a solicitation of an offer to buy any security, nor investment, legal or tax advice. Forward-looking statements — including the launch target and regulatory timetable — reflect current expectations and are subject to change. The company undertakes no obligation to update them.